Gastric bypass as a model to study type-two diabetes (with a focus on DNA methylation and sncRNA)
To date gastric bypass is the most effective treatment for type-two diabetes. Many patients leave hospital as little as 18h post-laproscopic surgery off, or on significantly reduced, diabetes medication. We are fortunate to collaborate with a gastro-intestinal surgeon who has built up a tissue bank from individuals (with and without type-two diabetes) who have undergone gastric bypass. For a small number of patients, samples are also available post-operatively, after significant weight-loss and amelioration of type-two diabetes and other metabolic phenotypes.
I’ll take you on a wander through some of our work to date, including comparing adipose tissue before and after gastric bypass, an initial comparison of the jejunum (part of the small intestine) in patients with/without type-two diabetes, and some work on small-non-coding RNA biomarkers in blood. There’ll also be the odd, related, digression – such as an exploration of the DNA methylome in livers from premature guinea pigs!
|Date||Tuesday, 10 March 2020|
|Time||12:00pm - 1:00pm|
|Event Category||Health Sciences|
|Location||New Biochemistry Seminar Room G.13|